Hematopoietic stem cell expansion and gene therapy.

@article{Watts2011HematopoieticSC,
  title={Hematopoietic stem cell expansion and gene therapy.},
  author={Korashon L. Watts and Jennifer E. Adair and Hans-Peter Kiem},
  journal={Cytotherapy},
  year={2011},
  volume={13 10},
  pages={
          1164-71
        }
}
Hematopoietic stem cell (HSC) gene therapy remains a highly attractive treatment option for many disorders, including hematologic conditions, immunodeficiencies including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), and other genetic disorders such as lysosomal storage diseases. In this review, we discuss the successes, side-effects and limitations of current gene therapy protocols. In addition, we describe the opportunities presented by implementing ex vivo… Expand
Haematopoietic stem cell reprogramming and the hope for a universal blood product
TLDR
An overview of the haematopoietic reprogramming methods reported to date is presented, the appropriate historical context is provided and critical insight is offered about where the field stands at present. Expand
An update on gene therapy for lysosomal storage disorders
TLDR
Gene therapy is still in its infancy with respect to LSDs, however, efficacy and safety has been demonstrated in numerous pre-clinical studies, and promising clinical results suggest that gene therapy treatment for several LSDs is a real possibility. Expand
Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist.
TLDR
It is revealed that in vitro culture of adult HSPC in AhRA maintains but does not increase the number of in vivo engrafting cells and that H SPC expanded in vitro contain defects in lymphopoiesis as assessed in this model system. Expand
Differentiation of human induced pluripotent stem cells into erythroid cells
TLDR
The in vitro production of human iPSC-derived RBCs can be an alternative treatment option for patients with blood disorders and an overview of the current status and applications of this field is presented. Expand
A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor.
TLDR
These studies describe a fundamental enhancement of the CGS expansion platform, identify a novel precursor population in the erythroid/megakaryocytic differentiation pathway of humans, and implicate an erythropoietin-independent, macrophage-associated pathway supporting terminal erythroblasts in this expansion system. Expand
Disrupted Signaling through the Fanconi Anemia Pathway Leads to Dysfunctional Hematopoietic Stem Cell Biology: Underlying Mechanisms and Potential Therapeutic Strategies
TLDR
The evidence that supports the role of dysfunctional HSC biology in driving the etiology ofFanconi anemia is discussed and the insights gained using such disease models can be translated into potential novel therapeutic strategies for the treatment of the hematologic disorders in FA patients are considered. Expand
Clinical Safety and Applications of Stem Cell Gene Therapy
TLDR
The latest developments in gene therapy vectors, the stem cell transduction techniques, and the therapeutic applications under investigation are reviewed. Expand
Review: Biomimetic nanofibers in the ex vivo expansion of cord blood-derived hematopoietic stem cells
This review summarizes current strategies in the development of advanced nanofibrous polymer-based scaffolds via electrospinning, their applications in mimicking the extracellular matrix, and the useExpand
Chinese Medicine Protein and Peptide in Gene and Cell Therapy.
TLDR
A critical review on traditional Chinese medicine's proteins and peptides, accompanied with perspectives on the challenges and new directions for future research in this emerging frontier are presented. Expand
Genome Editing: Potential Treatment for Lysosomal Storage Diseases
TLDR
How targeted genome editing can be combined with hematopoietic stem cell transplantation and other approaches to be used for the treatment of a particular group of genetic diseases, the lysosomal storage disorders is discussed. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 60 REFERENCES
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning
TLDR
Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions, and lower toxic metabolites, indicating the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID. Expand
Large animal models of hematopoietic stem cell gene therapy
TLDR
Large animals continue to be useful to evaluate the efficacy and safety of gene therapy, and dogs with hematopoietic diseases have now been cured by HSC gene therapy. Expand
Ten years of gene therapy for primary immune deficiencies.
  • A. Aiuti, M. Roncarolo
  • Biology, Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2009
TLDR
Following recent advances in preclinical studies, lentiviral vectors are now being translated into new clinical approaches, such as Wiskott-Aldrich Syndrome, and will provide significant advantages in terms of natural gene regulation and reduction in the potential for adverse mutagenic events. Expand
Ex vivo gene transfer and correction for cell-based therapies
  • L. Naldini
  • Biology, Medicine
  • Nature Reviews Genetics
  • 2011
TLDR
This Review highlights the latest developments and the crucial challenges for cell-based therapies, with an emphasis on haematopoietic stem cell gene therapy, which is taken as a representative example given its advanced clinical translation. Expand
Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency
TLDR
In comparison with SCID-X1, ADA-SCID gene therapy presents a better safety profile and engraftment of multilineage transduced stem/progenitor cells, thanks to the use of nonmyeloablative preconditioning. Expand
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
TLDR
A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit. Expand
Survival of the Fittest
TLDR
How in vivo selection strategies can be used to make stem cell gene therapy applicable to the treatment of a wider scope of genetic diseases and patients is reviewed. Expand
Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation.
TLDR
It is suggested that very primitive hematopoietic progenitors are maintained in long-term marrow cultures, where they can be triggered into entering the cell cycle and continue normal programs of proliferation, differentiation, and self-renewal. Expand
Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation.
TLDR
A serum-free culture containing SCF, TPO, FGF-1, angiopoietin-like 5, and IGFBP2 supports an approximately 20-fold net expansion of repopulating human cord blood HSCs, a number potentially applicable to several clinical processes including HSC transplantation. Expand
T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years
TLDR
It is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease. Expand
...
1
2
3
4
5
...